Advanced Medical Solutions Group plc (AMS.L), on Wednesday, issued a trading update for the year ended 31 December 2023, and said full-year 2023 results are expected to finish towards the middle of its published guidance ranges of £124 million - £127 million for revenue and £25 million - £27 million for adjusted profit before tax.
Chris Meredith, Chief Executive Officer of AMS, commented: "I am delighted with the strategic progress we have made across the Group in 2023, creating significant new opportunities for AMS. The completion of the new US LiquiBand route to market strategy, the US Connexicon acquisition and the roll-out of LiquiBand XL will support the delivery of record US LiquiBand revenues in 2024 and sets us up strongly to deliver our target of doubling our market share over the next five years."
Further, the company stated that with the US launch of LiquiFix progressing well and continued growth being generated from more established brands such as RESORBA and ActivHeal, the company is confident that the Group will generate strong and sustainable growth in 2024 and in the long term.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.